Fig. 1: Patient disposition as of the data cutoff (March 14, 2023) and analysis groups. | Leukemia

Fig. 1: Patient disposition as of the data cutoff (March 14, 2023) and analysis groups.

From: Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Fig. 1: Patient disposition as of the data cutoff (March 14, 2023) and analysis groups.

Disposition and analysis sets include patients with CML-CP without BCR::ABL1T315I mutations who received asciminib monotherapy. AE adverse event, ALL acute lymphoblastic leukemia, AP accelerated phase, BP blast phase, CML chronic myeloid leukemia, CP chronic phase, IS International Scale, MMR major molecular response (BCR::ABL1IS ≤ 0.1%); MR4, BCR::ABL1IS ≤ 0.01%; MR4.5, BCR::ABL1IS ≤ 0.0032%; Ph +  Philadelphia chromosome positive, PK pharmacokinetic, TFR treatment-free remission. aTreatment ongoing as of the cutoff date (March 14, 2023) in post-trial access, including patients who continued to receive asciminib in a rollover study or commercial availability. bOther reasons included treatment free remission attempt (n = 2) and other comorbidities (n = 1). cNine patients were excluded due to having atypical or unknown BCR::ABL1 transcripts at screening. From Mauro MJ, et al. Leukemia. 2023;37:1048-59 [16].

Back to article page